RAVER2

Across TCGA pan-cancer cohorts, RAVER2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAVER2 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAVER2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAVER2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where RAVER2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.929	0.517	.008	8	view →
CCRCC	OS	Tertile	All	0.904	0.736	.023	6	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	5	view →
PDAC	DFS	Tertile	All	0.910	0.685	.043	5	view →
GBM	OS	Median	All	0.626	0.450	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAVER2–LUAD (DFS)

Open the LUAD breakdown →